EMA Authorised: Wilzin (zinc) — Recordati Rare Diseases

View source ↗

Summary

The European Medicines Agency authorized Wilzin, a zinc-containing medicine, for Wilson disease (hepatolenticular degeneration) in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wilson Disease

Drugs mentioned

• Wilzin (zinc)

Snippet

Status: Authorised. Therapeutic area: Hepatolenticular Degeneration. MAH: Recordati Rare Diseases. Decision date: 16/12/2024